SAN DIEGO, August 12, 2016 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced a presentation at Rejuvenation Biotechnology 2016 (RB2016). RB2016 is hosted by the SENS Research Foundation and is taking place August 16th to 17th at the Buck Institute for Research on Aging in Novato, California.
Details of the presentations are as follows:
Panel: Session 6: The End User Is The Patient… And The Clinician
Speaker: Dr. Mark Zimmerman, Vice President, Strategy and Business Development
Date/Time: August 17, 3:15 pm PDT
For more information about ViaCyte’s participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/
ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte’s product candidates are based on the derivation of pancreatic progenitor cells, which are then implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. ViaCyte has two products in development. PEC-Direct product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for type 1 diabetes patients that have severe hypoglycemic episodes, extreme glycemic lability, and/or impaired awareness of hypoglycemia. The PEC-EnCap (formerly VC-01™) product candidate delivers pancreatic progenitor cells in an immunoprotective device and is currently being evaluated in a Phase 1/2 trial in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine and JDRF.
For more information on the clinical trial, called STEP ONE, please visit https://clinicaltrials.gov/ct2/show/NCT02239354.